EBITDA Margin % is the ratio of EBITDA divided by net sales or Revenue. It is an performance metric measuring company's operating profitability. EBITDA Margin takes depreciation and amortization, interest expense and tax into account, which makes it easy to compare the relative profitability of companies of different sizes in the same industry.
Beximco Pharmaceuticals EBITDA Margin % Related Terms
Beximco Pharmaceuticals EBITDA Margin % Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Beximco Pharmaceuticals's EBITDA Margin %, along with its competitors' market caps and EBITDA Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Beximco Pharmaceuticals EBITDA Margin % vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Beximco Pharmaceuticals's EBITDA Margin % distribution charts can be found below:
* The bar in red indicates where Beximco Pharmaceuticals's EBITDA Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Beximco Pharmaceuticals (BXMPY) has a EBITDA Margin % of 21.19% as of Dec. 2024. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Beximco Pharmaceuticals and its competitors. This is 11% below median its historical median of 23.89. Over the past decade, Beximco Pharmaceuticals' EBITDA Margin % has ranged from 22.46 to 26.77.
Is Beximco Pharmaceuticals' EBITDA Margin % too high?
Beximco Pharmaceuticals' current EBITDA Margin % of 21.19% is 11% below median its 10-year median of 23.89. Over the past 10 years, this metric has ranged from a low of 22.46 to a high of 26.77. The Drug Manufacturers industry median EBITDA Margin % is 12.44. Beximco Pharmaceuticals' value of 21.19% is 70.3% above this industry median. Overall, Beximco Pharmaceuticals has a GF Score™ of 97/100, reflecting its overall financial health beyond just this single metric.
How does Beximco Pharmaceuticals' EBITDA Margin % compare to ZTS and UTHR?
Beximco Pharmaceuticals' EBITDA Margin % of 21.19% can be compared against companies in the Drug Manufacturers industry. The industry median EBITDA Margin % is 12.44. Beximco Pharmaceuticals' value of 21.19% is 70.3% above this benchmark. Historically, Beximco Pharmaceuticals' own EBITDA Margin % has ranged from 22.46 to 26.77 over the past decade. While the company's 10-year median is 23.89 vs. the industry median of 12.44, Beximco Pharmaceuticals has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBITDA Margin % for a Drug Manufacturers company?
The median EBITDA Margin % among Drug Manufacturers companies is 12.44, based on 955 companies in the industry. Companies in the top quartile (top 25%) have a EBITDA Margin % significantly above this median, while those in the bottom quartile fall well below. However, EBITDA Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Beximco Pharmaceuticals's current EBITDA Margin % of 21.19% is 70.3% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBITDA Margin % mean?
A high EBITDA Margin % can signal that a stock is expensive relative to its fundamentals. EBITDA Margin is the ratio of EBITDA divided by net sales or Revenue, usually presented in percent. View historical data on Beximco Pharmaceuticals and its competitors. For the Drug Manufacturers industry, the median EBITDA Margin % is 12.44 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Beximco Pharmaceuticals's current EBITDA Margin % is 21.19%, which is 11% below median its own 10-year median of 23.89. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Beximco Pharmaceuticals stock overvalued right now?
Beximco Pharmaceuticals (BXMPY) has a current EBITDA Margin % of 21.19%. The current EBITDA Margin % is 21.19%, which is 11% below median its 10-year median of 23.89 and 70.3% above the Drug Manufacturers industry median of 12.44. Beximco Pharmaceuticals' overall GF Score™ is 97/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBITDA Margin % calculated?
EBITDA Margin % is calculated from a company's financial statements. For Beximco Pharmaceuticals (BXMPY), the current EBITDA Margin % is 21.19% as of Dec. 2024. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Beximco Pharmaceuticals PLC is engaged in manufacturing and marketing a wide range of generic pharmaceutical formulation products, life-saving intravenous fluids, therapeutic nutrition products, and Active Pharmaceutical Ingredients. It manufactures various pharmaceutical products including oral contraceptives, hormones, steroids, anti-histamine, anti-fibrinolytic, cardiac, musculoskeletal, respiratory, vitamin & mineral supplements, women's health products, and others. The products of the company are sold in domestic and international markets. Key revenue accrues from domestic sales.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BXMPY has been successfully added to your 